Company Description
Medifast, Inc. (NYSE: MED) is a health and wellness company that focuses on weight management and metabolic health through a science-backed, coach-guided lifestyle system. The company is widely known for its OPTAVIA-branded programs, which are designed to address obesity, support healthier lifestyles, and tackle the broader challenge of metabolic dysfunction. Medifast describes itself as a 40+ year old company with a long clinical heritage and an emphasis on evidence-based approaches to improving health.
According to multiple company communications, Medifast’s core offering is a habit-based, coach-guided lifestyle system. This system integrates personalized plans, scientifically developed products, and a framework for habit creation, all reinforced by a network of independent coaches. These coaches provide guidance, accountability, and community support for individuals pursuing weight loss, lifestyle change, and improved metabolic health. Medifast highlights that clients working with coaches on its Optimal Weight 5 & 1 Plan have achieved substantially greater weight and fat loss compared to self-directed approaches, based on published clinical research.
From Weight Loss to Metabolic Health
Medifast has described a strategic evolution from being primarily a weight-loss company to positioning itself as a metabolic health company. The company emphasizes that metabolic dysfunction is a widespread issue among U.S. adults and presents its programs as designed to address this underlying problem rather than focusing only on the number on the scale. Its communications repeatedly reference metabolic health as the foundation of overall well-being, energy, and long-term vitality.
As part of this shift, Medifast introduced Metabolic Synchronization™, which it characterizes as a breakthrough science that reverses metabolic dysfunction through a targeted reset of the body’s metabolism. Company materials state that research shows its comprehensive system activates strong and targeted fat burning to enhance metabolic health and body composition by reducing visceral fat, preserving lean mass, and protecting muscle. Medifast presents Metabolic Synchronization as an evolution of the science underlying its existing programs, expanding the focus from weight loss alone to broader metabolic outcomes.
OPTAVIA and Coach-Guided Lifestyle System
Medifast’s primary commercial platform is OPTAVIA®, described as a habit-based and coach-guided lifestyle solution. OPTAVIA is presented as a simple yet comprehensive approach to address obesity and support a healthy lifestyle. The company highlights several core elements of this system:
- Personalized lifestyle plans with clinically studied health benefits.
- Scientifically developed products that are integrated into structured programs such as the Optimal Weight 5 & 1 Plan®.
- A framework for habit creation, intended to help individuals build sustainable healthy routines.
- A network of independent coaches who provide one-on-one support, community, and guidance.
Medifast emphasizes that OPTAVIA coaches play a central role in client success, describing them as the “heartbeat” of the system. Company statements note that people working with an OPTAVIA coach on the Optimal Weight 5 & 1 Plan achieved significantly greater weight and fat loss than those attempting to lose weight on their own, based on a randomized controlled trial published in a peer-reviewed journal.
Scientific and Clinical Foundation
Medifast repeatedly underscores its scientific and clinical foundation. The company cites more than 40 years of clinical heritage, 30+ research studies, 70+ scientific abstract presentations and publications, and over 30 publications in peer-reviewed scientific journals. It maintains an in-house Scientific & Clinical Affairs team and an independent Scientific Advisory Board composed of physicians, academic researchers, and experts in areas such as nutrition, exercise science, and bio-behavioral science.
Recent company communications highlight specific research themes, including:
- Evidence that the Optimal Weight 5 & 1 Plan can preserve a high percentage of lean mass over a 16-week period, based on clinical trial data analyzed by Medifast scientists.
- Studies examining the long-term effects of anti-obesity medications and the importance of integrating lifestyle strategies such as nutrition therapy, behavioral support, and self-monitoring.
- Research on associations between sleep duration and quality and the risk of obesity, diabetes, and metabolic syndrome, emphasizing sleep as a pillar of preventive and metabolic health.
Through conference presentations, such as those at ObesityWeek, and ongoing research initiatives, Medifast presents itself as contributing to the scientific understanding of metabolic health and weight management.
Metabolic Synchronization™ and Quality Weight Loss
In its description of Metabolic Synchronization™, Medifast frames “quality weight loss” as the first step in improving metabolic health. Company materials state that its system supports:
- Targeted reduction of visceral fat, sometimes described as “bad fat” stored around organs and muscles.
- Preservation of lean mass, which the company links to basal metabolic rate, strength, energy, and mobility.
- Protection of muscle to support an active metabolism and more efficient energy use.
Medifast positions these outcomes as key mechanisms by which its programs address metabolic dysfunction and support healthier body composition. The company presents Metabolic Synchronization as a framework that can be applied across different client journeys, whether individuals are using weight-loss medications or pursuing a medication-free approach.
Collaboration and Access to GLP-1 Medications
Medifast has disclosed a collaboration with national virtual primary care provider LifeMD® and its affiliated medical group. Through this collaboration, the company states that clients or customers can have access to GLP-1 medications where clinically appropriate. Medifast also notes that medical advice, treatment, prescriptions, and the practice of medicine must be provided by licensed healthcare professionals, and that OPTAVIA coaches do not provide medical services.
This collaboration is presented as a way to integrate medically supported weight-loss options with Medifast’s lifestyle and behavioral support programs, particularly in the context of the growing use of GLP-1 medications for weight management.
Mission and Long-Term Focus
Across its public communications, Medifast consistently references its mission of “Lifelong Transformation, Making a Healthy Lifestyle Second Nature®”.> The company describes this mission as guiding its efforts to help individuals move beyond short-term dieting toward sustainable lifestyle change and improved metabolic health. It emphasizes community-driven support, coach guidance, and habit formation as central tools for achieving that mission.
Medifast also highlights that it is addressing what it calls a metabolic health crisis, citing external research indicating that a large majority of U.S. adults are metabolically unhealthy. By focusing on metabolic dysfunction, the company positions its programs as relevant not only for weight loss but also for broader aspects of health, vitality, and healthspan.
Corporate and Governance Highlights
Medifast’s common stock trades on the New York Stock Exchange under the ticker MED. The company has reported that it operates with no debt and maintains cash, cash equivalents, and investment securities on its balance sheet, based on recent quarterly financial releases. Shareholders have approved amendments to the company’s share incentive plan, increasing the number of shares authorized for issuance under that plan, as disclosed in an 8-K filing related to its annual meeting.
Recent SEC filings also describe executive leadership changes and succession planning. These include the planned transition of the current Chief Executive Officer to a non-executive Chairman role and the promotion of an internal executive to President, with expectations around future CEO succession. The company has also reported changes in certain executive roles and related compensation arrangements, as detailed in its Form 8-K filings.
Business Model Characteristics
While Medifast’s detailed revenue model is not fully described in the provided materials, the company consistently characterizes its business around:
- A direct-to-consumer orientation, with structured programs and products delivered alongside coaching support.
- A network of independent OPTAVIA coaches, whose activity levels and productivity are discussed in the company’s financial results.
- Ongoing investment in scientific research and clinical studies to support and refine its programs.
Company earnings releases reference metrics such as the number of active earning OPTAVIA coaches and revenue per active earning coach, underscoring the importance of the coach network to Medifast’s operations.
Position Within Health and Wellness
Medifast presents itself as a health and wellness company with a focus on obesity, metabolic health, and lifestyle change. It emphasizes that its approach is science-backed, coach-guided, and habit-based, and that it seeks to address both visible outcomes like weight loss and underlying factors such as metabolic function, body composition, and behavioral patterns. Through its OPTAVIA programs, Metabolic Synchronization framework, and scientific initiatives, the company aims to support individuals across different stages of their health journeys.
Stock Performance
Medifast (MED) stock last traded at $9.59, up 1.04% from the previous close. Over the past 12 months, the stock has lost 30.8%, ranking #1,798 in 52-week price change. At a market capitalization of $105.4M, MED is classified as a micro-cap stock with approximately 11.0M shares outstanding.
Latest News
Medifast has 10 recent news articles, with the latest published 6 days ago. Of the recent coverage, 5 articles coincided with positive price movement and 5 with negative movement. Key topics include earnings, earnings date, management. View all MED news →
SEC Filings
Medifast has filed 5 recent SEC filings, including 2 Form 8-K, 1 Form SCHEDULE 13D, 1 Form 10-K, 1 Form SCHEDULE 13G/A. The most recent filing was submitted on March 20, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all MED SEC filings →
Financial Highlights
Medifast generated $385.8M in revenue over the trailing twelve months, retaining a 71.3% gross margin, operating income reached -$14.2M (-3.7% operating margin), and net income was -$18.7M, reflecting a -4.8% net profit margin. Diluted earnings per share stood at $-1.70. The company generated $6.9M in operating cash flow. With a current ratio of 4.69, the balance sheet reflects a strong liquidity position.
Upcoming Events
Annual shareholder meeting
CEO transition
CEO succession
Medifast has 3 upcoming scheduled events. The next event, "Annual shareholder meeting", is scheduled for May 19, 2026 (in 54 days). Investors can track these dates to stay informed about potential catalysts that may affect the MED stock price.
Short Interest History
Short interest in Medifast (MED) currently stands at 2.0 million shares, down 7.1% from the previous reporting period, representing 18.9% of the float. Over the past 12 months, short interest has increased by 45.2%. This moderate level of short interest indicates notable bearish positioning. The 9.8 days to cover indicates moderate liquidity for short covering.
Days to Cover History
Days to cover for Medifast (MED) currently stands at 9.8 days, up 16.9% from the previous period. This moderate days-to-cover ratio suggests reasonable liquidity for short covering, requiring about a week of average trading volume. The days to cover has increased 41.4% over the past year, indicating either rising short interest or declining trading volume. The ratio has shown significant volatility over the period, ranging from 4.3 to 18.4 days.
MED Company Profile & Sector Positioning
Medifast (MED) operates in the Personal Services industry within the broader Miscellaneous Food Preparations & Kindred Products sector and is listed on the NYSE. In monthly performance, the stock ranks #1,367 among all tracked companies.
Investors comparing MED often look at related companies in the same sector, including Regis Corp (RGS), WW International Inc (WW), Stonemor Inc (STON), Smart Share Global Ltd (EM), and Carriage Svcs Inc (CSV). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate MED's relative position within its industry.